​Praxis Precision Medicines saw its stock soar by 100% on Thursday, following encouraging late-stage results for its experimental essential tremor treatment, ulixacaltamide. The Boston-based biotech company reported significant improvements in symptoms among patients who participated in its Essential3 Phase 3 program, sending a wave of optimism through both medical and investment communities. Essential tremor is […] The post Praxis stock skyrockets 100% after tremor drug breakthrough appeared first on Rolling Out.